Incyte Corporation (INCY)
Incyte: Buy For The Turnaround, Stay For The Pipeline
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.
Incyte's Pipeline Potential Signals Massive Upside For Investors
Incyte is a rare, profitable biotech with earnings doubling since 2021, driven by its core hematology franchise and rapidly expanding dermatology and oncology portfolios. INCY's non-Jakafi portfolio is rapidly expanding, with Opzelura and oncology assets driving double-digit growth and significant margin improvement. Management targets 15–20% five-year sales CAGR and $3–4B ex-Jakafi revenue by 2030, diverging from consensus' negative growth view.
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Incyte's blood cancer therapy meets main goal in late-stage trial
Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
